- €3.11bn
- €3.07bn
- €1.09bn
- 67
- 44
- 19
- 36
C2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 444 | 598 | 584 | 863 | 1,089 |
Cost of Revenue | |||||
Gross Profit | 165 | 195 | 183 | 316 | 402 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 335 | 478 | 493 | 658 | 822 |
Operating Profit | 109 | 119 | 90.3 | 204 | 267 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 101 | 115 | 75.6 | 204 | 258 |
Provision for Income Taxes | |||||
Net Income After Taxes | 89.9 | 111 | 74.1 | 202 | 232 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 90.2 | 110 | 72.7 | 202 | 233 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 90.2 | 110 | 72.7 | 202 | 233 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.68 | 3.29 | 2.19 | 5.64 | 6.24 |
Dividends per Share |